A landmark tuberculosis study showed that drug-sensitive TB can be treated in four months instead of six using the WHO-endorsed HPMZ regimen. This factsheet examines barriers to adoption, the role of new fixed-dose combinations, Global Fund GC8 funding opportunities, and advocacy strategies to expand access
The White House Office Of Management and Budget (OMB) under the direction of Russell Vought is seeking a regulatory blessing to use Federal grant funding as a tool for political extortion, violation of due process, and further undermining of scientific integrity. Targets include scientists, institutions, organizations, States, cities, and other recipients who might fail an extreme right wing, Christian nationalist, anti-science political litmus test.
The ASCENT DR-TB project, funded by Unitaid and led by the KNCV Tuberculosis Foundation, aims to improve access to shorter, safer and more effective treatment regimens for drug-resistant TB (DR-TB) and comprehensive, person-centered packages of quality care.
The United States is currently at an inflection point in Hepatitis C virus (HCV) response. We have the tools for rapid and accurate diagnosis, safe and effective cure, and prevention. These tools are only as useful as access to them can be, which is why the Cure Hepatitis C Act (S.1941) holds so much promise.
Forty-five years ago the Centers for Disease Control and Prevention (CDC) published a brief report describing five cases of a rare pneumonia among young gay men in Los Angeles. The report occupied just a few paragraphs in the Morbidity and Mortality Weekly Report (MMWR). No one reading it could have known that it marked the beginning of one of the deadliest epidemics in modern history.
TAG and KNCV are excited to present an upcoming webinar: Using Digital Storytelling and AI for Active Drug Safety Monitoring in Tuberculosis Care on Tuesday, June 20, at 9 a.m. EST. This is the latest installment in the series of virtual trainings for community and civil society organizations hosted by TAG under the Unitaid-funded ASCENT DR-TB Project.
TAG and the Long-Acting Therapies Community Advisory Board (LAT CAB) welcomed a decision by the Indian Patent Office rejecting a patent application related to the hepatitis C treatment combination glecaprevir/pibrentasvir (G/P). Advocates say the decision could help reduce barriers to generic competition, lower treatment costs, and expand access to hepatitis C treatment in low- and middle-income countries disproportionately affected by the epidemic.
Treatment Action Group (TAG) is profoundly troubled by recent reporting that the NIH’s longstanding Notice of Funding Opportunity (NOFO) process is being interrupted and delayed by political interference.
The collapse of global health aid in 2025 revealed the fragility of health financing. Despite successes against TB and HIV in recent years, health aid has not generated sustainable, country-led financing for health. Now, governments are scrambling to fill funding gaps to provide life-saving care.
The Promise and Potential of Economic Reforms for Health The collapse of global health aid in 2025 revealed the fragility of health financing. Despite successes against TB and HIV in recent years, health aid from bilateral and multilateral donors has…
The Research in Action Awards are on Thursday, October 15 from 6-9 p.m. at The Angel Orensanz Foundation, 172 Norfolk St., in the Lower East Side. TAG’s premier fundraising event honors the brightest scientists, activists, and artists working to end HIV, TB, and HCV.
Learn more and buy tickets now!
